Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Entero Therapeutics ( (ENTO) ).
On February 3, 2025, Entero Therapeutics announced a significant restructuring of its Board of Directors. The company appointed Manpreet Uppal, Alson Niu, and Richard Joel Paolone as new directors, replacing Timothy Ramdeen, Alastair Riddell, and James Sapirstein. However, on February 5, 2025, Alson Niu resigned and was replaced by Eric Corbett. These changes are expected to impact the company’s governance structure, with the new directors bringing diverse expertise in capital markets, corporate finance, and legal matters.
More about Entero Therapeutics
YTD Price Performance: -15.38%
Average Trading Volume: 202,419
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.61M
For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.
